论文部分内容阅读
目的探讨不同新辅助化疗方案对乳腺癌患者近期疗效、安全性及Ki-67的影响。方法 80例乳腺癌患者,根据随机数字表法分为TE+环磷酰胺组(TEC组)与表柔比星+多西他赛组(TE组),各40例。TE组应用表阿霉素+多西他赛,TEC组在TE组的基础上联合环磷酰胺。结果两组治疗总有效率比较差异无统计学意义(P>0.05)。TEC组化疗后血液毒性发生率为80.00%,低于TE组的42.50%(P<0.05)。两组治疗后阳性率均低于治疗前(P<0.05),但两组治疗后Ki-67表达比较差异无统计学意义(P>0.05)。结论 TEC与TE对乳腺癌患者的近期疗效及Ki-67的影响相当,但TE的血液毒性作用低于TEC,适于临床应用。
Objective To investigate the effect of different neoadjuvant chemotherapy regimens on the short-term efficacy, safety and Ki-67 in patients with breast cancer. Methods Eighty patients with breast cancer were divided into TE + cyclophosphamide group (TEC group) and epirubicin + docetaxel group (TE group), 40 cases in each group according to random number table. TE was given epirubicin + docetaxel, TEC group combined with cyclophosphamide on the basis of TE group. Results There was no significant difference in the total effective rate between the two groups (P> 0.05). The incidence of hematologic toxicity in TEC group was 80.00% after chemotherapy, which was lower than that in TE group (42.50%, P <0.05). The positive rates of both groups after treatment were lower than those before treatment (P <0.05), but there was no significant difference in Ki-67 expression between the two groups after treatment (P> 0.05). Conclusion The effect of TEC and TE on the short-term efficacy and Ki-67 in patients with breast cancer is similar, but TE is less toxic than TEC and suitable for clinical application.